Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carl J Fichtenbaum

Showing results (11-20 of 166) with videos related to

Pageof 17
Sort By:
Clinical Pharmacokinetics|October 31, 2002
Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infectionCarl J Fichtenbaum, John G Gerber
HIV Clinical Trials|January 25, 2008
Short-term effect of HAART on blood pressure in HIV-infected individualsJodi M Grandominico, Carl J Fichtenbaum
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 3, 2020
Bearing the Burden of Non-AIDS Comorbidities: This Is What Women Aging With Human Immunodefiency Virus Look LikeMoises A Huaman, Carl J Fichtenbaum
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 4, 2001
Ischemic cardiovascular disease in persons with human immunodeficiency virus infectionMax H David, Richard Hornung, Carl J Fichtenbaum
Expert Opinion on Emerging Drugs|May 9, 2018
Emerging reverse transcriptase inhibitors for HIV-1 infectionMohammad A Rai, Sam Pannek, Carl J Fichtenbaum
Pathogens & Immunity|November 18, 2016
Elevated Circulating Concentrations of Interferon-Gamma in Latent Tuberculosis InfectionMoises A Huaman, George S Deepe, Carl J Fichtenbaum
Journal of Acquired Immune Deficiency Syndromes (1999)|August 7, 2003
Leptin replacement therapy but not dietary polyunsaturated fatty acid alleviates HIV protease inhibitor-induced dyslipidemia and lipodystrophy in miceTara M Riddle, Carl J Fichtenbaum, David Y Hui
AIDS (London, England)|October 15, 2011
High-sensitivity C-reactive protein levels do not decrease with the use of statins in all persons with HIV infectionCarl J Fichtenbaum, Scott E Evans, Judith A Aberg
HIV Clinical Trials|April 17, 2007
Comparison of direct and indirect measurement of LDL-C in HIV-infected individuals: ACTG 5087Scott R Evans, Carl J Fichtenbaum, Judith A Aberg, et al.
Journal of Clinical Pharmacology|June 30, 2011
Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatinDivya Samineni, Pankaj B Desai, Larry Sallans, et al.
Pageof 17

Showing results (11-20 of 166) with videos related to

Sort By:
Pageof 17
Clinical Pharmacokinetics|October 31, 2002
Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infectionCarl J Fichtenbaum, John G Gerber
HIV Clinical Trials|January 25, 2008
Short-term effect of HAART on blood pressure in HIV-infected individualsJodi M Grandominico, Carl J Fichtenbaum
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 3, 2020
Bearing the Burden of Non-AIDS Comorbidities: This Is What Women Aging With Human Immunodefiency Virus Look LikeMoises A Huaman, Carl J Fichtenbaum
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 4, 2001
Ischemic cardiovascular disease in persons with human immunodeficiency virus infectionMax H David, Richard Hornung, Carl J Fichtenbaum
Expert Opinion on Emerging Drugs|May 9, 2018
Emerging reverse transcriptase inhibitors for HIV-1 infectionMohammad A Rai, Sam Pannek, Carl J Fichtenbaum
Pathogens & Immunity|November 18, 2016
Elevated Circulating Concentrations of Interferon-Gamma in Latent Tuberculosis InfectionMoises A Huaman, George S Deepe, Carl J Fichtenbaum
Journal of Acquired Immune Deficiency Syndromes (1999)|August 7, 2003
Leptin replacement therapy but not dietary polyunsaturated fatty acid alleviates HIV protease inhibitor-induced dyslipidemia and lipodystrophy in miceTara M Riddle, Carl J Fichtenbaum, David Y Hui
AIDS (London, England)|October 15, 2011
High-sensitivity C-reactive protein levels do not decrease with the use of statins in all persons with HIV infectionCarl J Fichtenbaum, Scott E Evans, Judith A Aberg
HIV Clinical Trials|April 17, 2007
Comparison of direct and indirect measurement of LDL-C in HIV-infected individuals: ACTG 5087Scott R Evans, Carl J Fichtenbaum, Judith A Aberg, et al.
Journal of Clinical Pharmacology|June 30, 2011
Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatinDivya Samineni, Pankaj B Desai, Larry Sallans, et al.
Pageof 17